Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
OBJECTIVE
To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.


METHODS
Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of daunorubicin (5 microg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.


RESULTS
Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best-corrected visual acuity of >or=3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.


CONCLUSIONS
Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.
Kumar
Atul
A
Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. akum66mm@ndf.vsnl.net.in
Nainiwal
Sanjeev
S
Choudhary
Indranil
I
Tewari
Hem K
HK
Verma
Lalit K
LK
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000150:complications / Q000601:surgery*; D012591:Scleral Buckling; D014792:Visual Acuity; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000209:etiology / Q000517:prevention & control*; D014822:Vitreous Body
D000903:Antibiotics, Antineoplastic; D003630:Daunorubicin